Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for drug-resistant epilepsy in tuberous sclerosis complex
2024-515937-13-00Phase 3Authorised
- Sponsor
- Children's Memorial Health Institute
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and tuberous sclerosis complex (TSC) comparing Rapamune with Placebo (2 arms). Planned start Feb 2023; status: authorised.
02
Drugs
sirolimus
03
Conditions
epilepsytuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2024-515937-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515937-13-00.